摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N6-methyl-8-oxoadenosine | 154939-21-6

中文名称
——
中文别名
——
英文名称
N6-methyl-8-oxoadenosine
英文别名
9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-(methylamino)-7H-purin-8-one
N<sup>6</sup>-methyl-8-oxoadenosine化学式
CAS
154939-21-6
化学式
C11H15N5O5
mdl
——
分子量
297.271
InChiKey
SWJYOKZMYFJUOY-KQYNXXCUSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 密度:
    1.708±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -1.8
  • 重原子数:
    21
  • 可旋转键数:
    3
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    140
  • 氢给体数:
    5
  • 氢受体数:
    8

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    N6-methyl-8-oxoadenosine盐酸 作用下, 反应 96.0h, 生成 6-Amino-9-methyl-7H-purin-8(9H)-one
    参考文献:
    名称:
    Purines. LXXIV. Syntheses and Rearrangements of 8-Oxoadenines Monomethylated at the N6-, 1-, and 3-Positions.
    摘要:
    用沸腾的 2 N 盐酸处理 48 小时后,N6-甲基-8-氧代腺嘌呤核苷(1)、1-甲基-8-氧代腺嘌呤核苷(5)和 7-甲基-8-氧代腺嘌呤核苷(8)发生糖苷水解,但速度比相应的 8-未取代化合物慢得多,生成的缩醛(2、6 和 9)的产率为 45%-63%。在这些条件下,N6-甲基-8-氧代腺嘌呤(2)重新排列为 9-甲基-8-氧代腺嘌呤(3)(收率 8%),这可能是通过咪唑环的裂变和再封闭实现的。3- 甲基-8-羟基腺嘌呤(7)也发生了明显的甲基迁移,在类似条件下,用盐酸处理后可得到 1-甲基-8-氧代腺嘌呤(6),产率为 9%。
    DOI:
    10.1248/cpb.44.2318
  • 作为产物:
    描述:
    8-氧腺苷sodium hydroxide 作用下, 以 N,N-二甲基乙酰胺 为溶剂, 反应 8.0h, 生成 N6-methyl-8-oxoadenosine
    参考文献:
    名称:
    Saito; Kanai; Fujii, Chemical and Pharmaceutical Bulletin, 1993, vol. 41, # 10, p. 1850 - 1852
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Novel methods for the delivery of polynucleotides to cells
    申请人:——
    公开号:US20030235916A1
    公开(公告)日:2003-12-25
    Process are described for the delivery of a polynucleotide to a cell. The process comprises forming a salt stable complex between the polynucleotide and a cationic surfactant. Ternary complexes are also made by associating an amphipathic compound with the binary complex. The resultant complexes are suitable for delivery of the polynucleotide to cells in vitro and in vivo.
    描述了将多核苷酸传递到细胞的过程。该过程包括在多核苷酸和阳离子表面活性剂之间形成一个盐稳定的复合物。三元复合物也可以通过将一个两性化合物与二元复合物结合而制备。所得的复合物适用于体外和体内向细胞传递多核苷酸。
  • Salutaridine reductase and morphine biosynthesis
    申请人:Leibniz-Institut für Pflanzenbiochemie (IPB)
    公开号:EP1837396A1
    公开(公告)日:2007-09-26
    Plants of the order Ranunculales, especially members of the species Papaver, accumulate a large variety of benzylisoquinoline alkaloids with about 2,500 structures. But only the opium poppy, Papaver somniferum, and Papaver setigerum, are able to produce morphinan alkaloids such as the analgesic morphine or the antitussive codeine. We investigated the molecular basis for this exceptional biosynthetic capability by comparison of alkaloid profiles with gene expression profiles between sixteen different Papaver species and identified one cDNA which exhibits very similar expression pattern to previously isolated cDNAs coding for enzymes in benzylisoquinoline biosynthesis and which showed the highest amino acid identity to reductases in menthol biosynthesis. When expressed, the protein encoded by this cDNA reduced the keto group of salutaridine yielding salutaridinol, an intermediate in morphine biosynthesis. The stereoisomer epi-salutaridinol was not formed. The encoded protein was identified as salutaridine reductase (SalR; EC 1.1.1.248) and it was found to belongs to the family of the short chain dehydrogenases / reductases.
    毛茛目植物,尤其是罂粟属物种,积累了大量的苯基异喹啉生物碱,约有2500种结构。但只有鸦片罂粟(Papaver somniferum)和刺毛罂粟(Papaver setigerum)等品种能够产生吗啡等镇痛药物吗啡类生物碱或镇咳药可待因。我们通过比较16种不同罂粟属植物的生物碱谱与基因表达谱,鉴定出一个cDNA,其表达模式与之前分离的编码苯基异喹啉生物合成酶的cDNA非常相似,并且与薄荷醇生物合成中的还原酶具有最高的氨基酸同源性。当表达时,这个cDNA编码的蛋白质将沙洛特啶的酮基还原为沙洛特啉醇,这是吗啡生物合成中的中间体。而对映异构体外沙洛特啉醇并未形成。这个编码的蛋白质被鉴定为沙洛特啶还原酶(SalR;EC 1.1.1.248),并且发现它属于短链脱氢酶/还原酶家族。
  • Charge reversal of polyion complexes and treatment of peripheral occlusive disease
    申请人:——
    公开号:US20030236214A1
    公开(公告)日:2003-12-25
    A process is described for the delivery of a therapeutic polynucleotide to a tissue suffering from or potentially suffering from ischemia. An ionic polymer is utilized in “recharging” (another layer having a different charge) a condensed polynucleotide complex for purposes of nucleic acid delivery to a cell. The resulting recharged complex can be formed with an appropriate amount of positive or negative charge such that the resulting complex has the desired net charge.
    描述了一种将治疗性多核苷酸递送到患有或潜在患有缺血的组织的过程。使用离子聚合物在“充电”(具有不同电荷的另一层)浓缩的多核苷酸复合物,以便将核酸递送到细胞中。形成的充电复合物可以具有适量的正或负电荷,使得形成的复合物具有所需的净电荷。
  • [EN] Gd(III)-DITHIOLANE GOLD NANOPARTICLE CONJUGATES<br/>[FR] CONJUGUÉS DE NANOPARTICULES D'OR ET DE GD(III)-DITHIOLANE
    申请人:UNIV NORTHWESTERN
    公开号:WO2016210290A1
    公开(公告)日:2016-12-29
    Provided herein are compositions Gd(III)-dithiolane gold nanoparticle conjugates and methods of use thereof. In particular, compositions and method find use in in vivo imaging (e.g., magnetic resonance imaging (MRI)), for example, of pancreatic tissue.
    本文提供了Gd(III)-二硫杂环己烷金纳米粒子共轭物的组合物及其使用方法。具体来说,这些组合物和方法可用于体内成像(例如磁共振成像(MRI)),例如胰腺组织的成像。
  • DENDRIMER CONJUGATES
    申请人:Baker, JR. James R.
    公开号:US20090287005A1
    公开(公告)日:2009-11-19
    The present invention relates to novel therapeutic and diagnostic dendrimers. In particular, the present invention is directed to dendrimer-linker conjugates, methods of synthesizing the same, compositions comprising the conjugates, as well as systems and methods utilizing the conjugates (e.g., in diagnostic and/or therapeutic settings (e.g., for the delivery of therapeutics, imaging, and/or targeting agents (e.g., in disease (e.g., cancer) diagnosis and/or therapy, pain therapy, etc.)). Accordingly, dendrimer-linker conjugates of the present invention may further comprise one or more components for targeting, imaging, sensing, and/or providing a therapeutic or diagnostic material and/or monitoring response to therapy.
    本发明涉及新型治疗和诊断性树状分子。具体而言,本发明涉及树状分子-连接物共轭物,其合成方法,包含该共轭物的组合物,以及利用该共轭物的系统和方法(例如,在诊断和/或治疗设置中(例如,用于传递治疗剂、成像和/或靶向剂(例如,在疾病(例如癌症)诊断和/或治疗、疼痛治疗等方面)。因此,本发明的树状分子-连接物共轭物可能进一步包括一个或多个用于靶向、成像、感应和/或提供治疗或诊断材料和/或监测治疗反应的组分。
查看更多